To investigate whether Ang II type-1 (AT1) receptor blockade could protect kidney mitochondria in streptozotocin-induced type-I diabetes, 8-week-old, male Sprague-Dawley rats received: a single streptozotocin injection (65 mg/kg, i.p.) (STZ group); streptozotocin and drinking water containing losartan (30 mg/kg/d) (STZ+Los group), or amlodipine (3 mg/kg/d) (STZ+Amlo group); or saline (i.p.) and pure water (Control group). Four-month long losartan or amlodipine treatments started 30 d prior to streptozotocin injection to improve the antioxidant defenses. Renal lesions, plasma glucose and lipids, and proteinuria were higher, and creatinine clearance was lower in STZ and STZ+Amlo versus STZ+Los and Control. Glycemia was higher in STZ+Los versus Control. Blood pressure, basal mitochondrial membrane potential, mitochondrial pyruvate, and renal oxidized glutathione were higher, and NADH/cytochrome c oxidoreductase activity lower, in STZ versus the other groups. In STZ and STZ+Amlo, mitochondrial H 2 O 2 production rate was higher, and uncoupling protein-2 content, cytochrome c oxidase activity and renal glutathione were lower than in STZ+Los and Control. Mitochondrial nitric oxide synthase activity was higher in STZ+Amlo versus the other groups. Mitochondrial pyruvate and H 2 O 2 production rate negatively contributed to electron transfer capacity, and positively contributed to renal lesions. Uncoupling protein-2 content negatively contributed to mitochondrial H 2 O 2 production rate and renal lesions. Renal glutathione reduction potential positively contributed to mitochondria electron transfer capacity. Concluding, AT1-blockade protects kidney mitochondria and kidney structure in streptozotocin-induced diabetes independently of blood pressure and glycemia.
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is both labile to oxidative conditions and highly relevant to prevent mtROS damage to other mitochondrial components (12). Finally, UCP-2 by regulating mitochondrial energy handling, can attenuate excessive mitochondrial superoxide production (5). The fact that whole kidney homogenates were used to isolate mitochondria does not allow to identify a kidney section, i.e. epithelium, cortex, or medulla, as the major source of mitochondria. However, it seems reasonable to assume that the mitochondria preparation used provides an approximation to tubular cell mitochondria considering that: i) rat kidneys consist of approximately 80% medullar and 20 % cortical tissue; ii) total medullary tubules amount to about 85 % of medullary volume;
and iii) of all the cell types that compose the kidney, medullar tubular cells have the highest number of mitochondria (32). and citrate synthase activity (220±14 µmol CoA/min.mg protein) were similar among groups. To better account for differences in mitochondrial yield, mitochondrial parameters were normalized to citrate synthase activity. In STZ, basal mtMP was 40%, 30%, and 46% higher than in STZ+Los, STZ+Amlo, and Control, respectively (p<0.05; Fig. 1A ). Malate/glutamate-supported mtMP was similar among groups (654±50 mV/mmol CoA.min -1 .mg protein -1 ). In STZ and
STZ+Amlo, H 2 O 2 production rate was approximately 40% higher than in STZ+Los and Control (p<0.05; Fig.1B ). In STZ, NADH/cytcOxRed activity was approximately 35% lower than in STZ+Los, STZ+Amlo, and 72% lower than in Control (p<0.05) (Fig. 1C) . In STZ+Los and
STZ+Amlo, NADH/cytcOxRed activity was 58% and 45% lower than in Control, respectively (p<0.05; Fig. 1C ). In STZ and STZ+Amlo, CytcOx activity was lower than in STZ+Los (-27%, and -19%, respectively; p<0.05) and Control (-27% and -19%, respectively; p<0.05; Fig. 1D ).
In STZ+Amlo, mtNOS activity was 13-, 27-, and 3-times higher than in STZ, STZ+Los and Control, respectively (Fig. 1E) . In STZ+Los and Control, Mn-SOD activity was approximately 3-and 2-times higher than in STZ and STZ+Amlo, respectively (Fig. 1F ). UCP-2 content was similar in STZ+Los and Control, and was lower in STZ and STZ+Amlo (Fig. 1G ).
In STZ, mitochondrial pyruvate was higher than in STZ+Los, STZ+Amlo, and Control (52%, 110%, and 175%, respectively; p<0.05) (Fig. 1H) . Multiple regression analysis (R 2 = 0.795; p<0.008) showed that mitochondrial pyruvate (p<0.01) and H 2 O 2 production rate (p<0.02) negatively contributed to electron transfer through complexes I to III, and UCP-2 content negatively contributed to mitochondrial H 2 O 2 production rate (p<0.04).
Losartan and amlodipine effects on renal glutathione. In STZ+Los and Control, GSH cont ent was 3-and 4-times higher (respectively) than in STZ+Amlo, and 8-and 12-times higher (respectively) than in STZ (p<0.05) (Fig. 2) . In STZ+Amlo, GSH content was 3-times higher than in STZ (p<0.05). In STZ+Los and STZ+Amlo, renal GSSG was 51% and 80% lower (respectively, p<0.05) than in STZ. In Control, GSSG content was 4-times higher than in STZ+Amlo (p<0.05). In STZ, the GSH/GSSG ratio was 94% lower than in STZ+Los, STZ+Amlo and Control (p<0.05) In STZ, E GSSG/2GSH was lower (p<0.05) than in STZ+Los (-32%), STZ+Amlo (-24%), and Control (-34%). In STZ+Amlo, E GSSG/2GSH was 10% lower than in Control and STZ+Los (p<0.05) (Fig. 2) . Multiple regression (R 2 =0.795; p<0.008) showed that E GSSG/2GSH positively contributed to electron transfer through complexes I to III (p<0.04).
Losartan and amlodipine effects on renal histology. Table 2 shows the quantification of the results in Fig. 3 -5. In STZ, glomerular and tubulointerstitial -SMA immunolabeling was markedly higher than in Control ( Fig. 3A vs 3D ; and 3E vs 3H). Accordingly, Col-III immunolabeling was higher in STZ than in Control ( Fig. 4A vs 4D ; and 4E vs 4H). In STZ+Los and STZ+Amlo ( Fig. 3B and 3C , respectively) glomerular -SMA immunolabeling was significantly lower than in STZ, but only in STZ+Los -SMA immunolabeling was similar to
Control. In STZ+Los (Fig. 3F ), but not in STZ+Amlo (Fig. 3G ) tubulointerstitial -SMA immunolabeling was significantly lower than in STZ. Col-III glomerular and tubulointerstitial immunolabeling in STZ+Los ( Fig. 4B and 4F , respectively) but not in STZ+Amlo ( Fig. 4C and   4G , respectively) were significantly lower than in STZ, and similar to Control. In STZ (Fig. 5A) and STZ+Amlo (Fig. 5C ), the walls of intrarenal arteries and arterioles were significantly thicker than in Control (Fig. 5D ) and STZ+Los (Fig. 5B) . In STZ and STZ+Amlo, a significant increase in glomerular sizes relative to Control and STZ+Los was observed ( 
DISCUSSION
In hyperglycemic streptozotocin-diabetic rats, losartan and amlodipine were equally potent antihypertensive agents, but only losartan was able to: i) improve mitochondrial In agreement with other studies (8, 49, 61), losartan prevented diabetes-related changes in lipid metabolism. The augmentation of basal mtMP observed in STZ may be a consequence of overactivation of mitochondrial electron transport, secondary to an overabundance of tricarboxylic acid cycle-derived respiratory substrates that resulted from an excessive availability of pyruvate, as was described in endothelial cells (59). Facilitative glucose transport is augmented in diabetic kidneys, as a result of changes in both, gene expression and cellular localization of glucose transporters (50). Glycolytic capacity is minimal in kidney proximal tubules, which depend exclusively on mitochondria for ATP production. Medullary nephron segments are highly glycolytic, resulting in high lactate generation. However, medullary anaerobic glycolysis does not seem to provide enough ATP to fully support sodium transport.
Notably, the medullary thick ascending limb exhibits the highest mitochondrial density along the mammalian nephron (32). These last two observations suggest that medullary thick ascending limb mitochondria may furnish the ATP that anaerobic glycolysis cannot provide. In this context, lactate, once considered merely a by-product of glycolysis, can be taken up by mitochondria and converted into pyruvate, which is fully oxidized by the respiratory chain (7). Evidences supporting the existence of this so-called ¨lactate shuttle¨ in skeletal muscle, liver, heart and brain (30) prompted us to consider that a lactate shuttle might exist in the kidney. Thus, in hyperglycemic rats, excess renal glucose reabsorption might result in increased medullar lactate production, increased mitochondrial lactate uptake, and finally higher mitochondrial pyruvate content. Supporting this hypothesis, in STZ kidneys, mitochondrial pyruvate was higher than in Control, and both losartan and amlodipine corrected this augmentation, notwithstanding that rats remained hyperglycemic. This increase in mitochondrial pyruvate in STZ, may contribute to the higher basal mtMP and H 2 O 2 production rate. This is not at variance with amlodipine being able to lower pyruvate content, but failing to lower H 2 O 2 production rate, since amlodipine cannot correct Ang II-induced mtROS production. The conversion of pyruvate into a tricarboxylic acid cycle substrate that is normally catalyzed by mitochondrial pyruvate dehydrogenase, can also be catalyzed by pyruvate carboxylase. This is relevant considering that: i) in diabetes, pyruvate dehydrogenase complex activity is depressed in several tissues, including the kidney (36); and ii) the amount of pyruvate entering into the tricarboxylic acid cycle by the pyruvate carboxylase route was 2-times higher than that entering through the pyruvate dehydrogenase route in the liver of streptozotocin-diabetic rats (14).
Drawing from current evidence, and supported by the present results, two mechanisms can be envisioned that may contribute to increased kidney mtROS production in diabetes. The Given the type of study design used, it is difficult to conclude whether the mitochondrial changes are causal to the observed structural and functional changes, or rather consequences of other beneficial effects of losartan, such as restoration of -adrenergic-dependent activation of glucose transporters (67), or modulation of PKC-dependent glucose uptake (52). In addition, it is important to indicate that an effect of losartan mediated by the induced decrease in hyperglycemia cannot be disregarded. However, the facts that: i) losartan lowered blood glucose levels to 337 mg/dl, a value that defines marked diabetes in rats; and ii) values closer to normal glycemia were unable to restore normal function in rat kidney, liver and heart mitochondria in streptozotocin-mediated diabetes (3, 39), suggest that it is unlikely that the observed mitochondrial actions of losartan may be ascribed to the observed modest decrease of hyperglycemia. Since glucose delivery to the kidney is not impaired in diabetes, mitochondrial decay in this organ seems to be unrelated to a lack of metabolic fuel, and, on the contrary, possibly results from excess glucose. Thus, the observed alterations in kidney mitochondria appear unrelated to the impaired nutrient availability in other tissues.
The present treatment design, i.e., administering losartan or amlodipine before the onset of diabetes, has the limitation of not representing a genuine therapeutical approach. However, the protective mitochondrial effects displayed by losartan may provide a potential mechanism to explain the reduction of type-2 diabetes incidence observed in hypertensive patients treated with RAS inhibitors (ACE inhibitors or AT1 receptor blockers) compared with other antihypertensive agents (75).
In summary, in streptozotocin-induced diabetes, kidney structural and functional protection by AT1-blockade would be mediated, at least partly, by attenuation of mitochondrial functioning impairment. These benefits were independent of both, systolic BP reduction and blood glucose levels, and point to Ang II as a relevant contributor to mitochondrial dysfunction in diabetes. 
Figure 2
Renal glutathione status in streptozotocin-diabetic rats treated during 4 months with losartan or amlodipine, and control rats. Values are means ± SE (n = 8 rats per group). 
Figure 5
Intrarenal arteriole wall thickness in streptozotocin-diabetic rats treated during 4 months with losartan or amlodipine, and control rats. Photomicrographs showing intrarenal arteriole in kidney slices immunolabeled with -SMA. In STZ, the walls of intrarenal arterioles were significantly thicker than in Control and STZ+Los.
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